Clinical Trial Update: Effect of Lactiplantibacillus Plantarum DAD-13 on Inflammatory Markers in ICU Sepsis Patients [NA]

View source ↗

Summary

Completed clinical trial assessing the probiotic Lactiplantibacillus plantarum DAD-13 for reducing inflammatory markers in ICU sepsis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness
• Sepsis
• Systemic Inflammatory Response Syndrome

Drugs mentioned

• Lactiplantibacillus plantarum DAD-13 (Lactiplantibacillus plantarum DAD-13)

Snippet

Sponsor: PT Royal Medikalink Pharmalab | Conditions: Sepsis, Systemic Inflammatory Response Syndrome (SIRS) | NA | Status: COMPLETED